PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-25.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
610.74%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
609.26%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
609.26%
Positive diluted EPS growth while CRVO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
320.27%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
320.27%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
419.54%
OCF/share CAGR of 419.54% while CRVO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
419.54%
OCF/share CAGR of 419.54% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
400.10%
Positive 3Y OCF/share CAGR while CRVO is negative. John Neff might see a big short-term edge in operational efficiency.
706.07%
10Y net income/share CAGR of 706.07% while CRVO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
706.07%
Net income/share CAGR of 706.07% while CRVO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
315.93%
Positive short-term CAGR while CRVO is negative. John Neff would see a clear advantage in near-term profit trajectory.
-251.89%
Negative equity/share CAGR over 10 years while CRVO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-251.89%
Negative 5Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-24.04%
Negative 3Y equity/share growth while CRVO is at 926.84%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.74%
Under 50% of CRVO's 1118.41%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-14.44%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
30.71%
SG&A declining or stable vs. CRVO's 76.17%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.